Skip to main content

Table 1 Baseline characteristics of children by subsequent tuberculosis (TB) status

From: Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy

 

TB

No TB

Total

P value

 

69 (7 %)

900 (93 %)

969

 

Age (at baseline)

 Median, IQR (years)

5 (2–11)

5 (2–9)

  

  < 3 years

31 (9)

307 (91)

338

0.07

Sex

 Male

28 (6)

460 (94)

488

0.09

 Female

41 (9)

440 (91)

481

 

Centre

 Entebbe

16 (9)

163 (91)

179

0.35

 JCRC

16 (6)

248 (94)

264

 

 Harare

14 (6)

243 (94)

257

 

 PIDC

23 (9)

246 (91)

269

 

Height (median IQR)

 Height-for-age Z score

−3.0 (−4.0 to –1.8)

−2.3 (−3.3 to –1.3)

 

<0.001

Weight (median IQR)

 Weight-for-age Z score

−2.8 (−4.1 to –1.8)

−1.8 (−2.8 to –0.9)

 

<0.001

WHO stage

 3 or 4

52 (8)

561 (92)

613

0.03

CD4 (median, IQR)

 CD4 %

8 (5–13)

13 (7–19)

 

0.001

 CD4 counta

136 (33–250)

253 (93–405)

 

0.07

Initial ART

 3TC ABC EFV

6 (6)

99 (94)

105

0.03

 3TC ABC NVP

24 (11)

190 (89)

214

 

 ZDV 3TC ABC EFV

9 (4)

217 (96)

226

 

 ZDV 3TC ABC NVP

30 (7)

394 (93)

30

 

Randomization

 A (3TC/ABC/NNRTI throughout)

30 (9)

289 (91)

319

 

 B (3TC/ABC/NNRTI throughout, ZDV until week 36)

24 (7)

301 (93)

325

 

 C (3TC/ABC/ZDV throughout, NNRTI until week 36)

15 (5)

310 (95)

325

0.06

Randomization

 Clinical monitoring

35 (7)

449 (93)

484

 

 Laboratory monitoring

34 (7)

451 (93)

485

0.89

  1. Values are n (row %) unless otherwise stated
  2. aIn those over 5 years
  3. 3TC Lamivudine, ABC Abacavir, EFV Efavirenz, IQR Interquartile range, JCRC Joint Clinical Research Centre, NNRTI Non-nucleoside reverse transcriptase inhibitor, NVP Nevirapine, PIDC Paediatric Infectious Diseases Clinic, ZDV Zidovudine